Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas

Diagn Cytopathol. 2003 Mar;28(3):142-6. doi: 10.1002/dc.10257.

Abstract

Detection of HER-2/neu alterations is increasingly used in breast cancer patients for therapeutic purposes. This study examines the reliability of HER-2/neu immunocytochemical assessment on 66 cytospin smears obtained by fine-needle aspiration biopsy from breast cancer patients. Results were compared with those obtained by both fluorescence in situ hybridization (FISH) on fine-needle aspirate (FNA) and immunohistochemistry (IHC) on matched histologic section. Concordance between immunocytochemistry (ICC) and FISH was 78% and between ICC and IHC was 84%. Discordance mainly concerned seven unamplified cases that resulted positive by ICC and four cases scored negative by IHC but positive by ICC. Simultaneous assessment of HER-2/neu by ICC, IHC, and FISH was available in 24 cases; the concordance was 75%. In this study, the false positivity of immunocytochemical technique represents the major criticism. In our experience, FISH remains the most objective and powerful technique for HER-2/neu assessment on breast cancer FNAs.

Publication types

  • Comparative Study
  • Evaluation Study

MeSH terms

  • Adenocarcinoma / genetics*
  • Adenocarcinoma / metabolism
  • Adenocarcinoma / pathology
  • Biopsy, Needle / methods*
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • False Positive Reactions
  • Female
  • Humans
  • Immunoenzyme Techniques / methods*
  • In Situ Hybridization, Fluorescence
  • RNA, Messenger / metabolism
  • Receptor, ErbB-2
  • Reproducibility of Results

Substances

  • RNA, Messenger
  • Receptor, ErbB-2